Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects

Abstract Background To investigate the effects of coadministration of esaxerenone with amlodipine on the pharmacokinetics (PK) of each drug, and of esaxerenone on the PK of digoxin. Methods In three open-label, single-sequence, crossover studies, healthy Japanese males received single oral doses of...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshiaki Kirigaya (Author), Masanari Shiramoto (Author), Tomoko Ishizuka (Author), Hinako Uchimaru (Author), Shin Irie (Author), Manabu Kato (Author), Takako Shimizu (Author), Takafumi Nakatsu (Author), Yasuhiro Nishikawa (Author), Hitoshi Ishizuka (Author)
Format: Book
Published: BMC, 2020-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c39e71805f0e44b8b24ece08b36c520b
042 |a dc 
100 1 0 |a Yoshiaki Kirigaya  |e author 
700 1 0 |a Masanari Shiramoto  |e author 
700 1 0 |a Tomoko Ishizuka  |e author 
700 1 0 |a Hinako Uchimaru  |e author 
700 1 0 |a Shin Irie  |e author 
700 1 0 |a Manabu Kato  |e author 
700 1 0 |a Takako Shimizu  |e author 
700 1 0 |a Takafumi Nakatsu  |e author 
700 1 0 |a Yasuhiro Nishikawa  |e author 
700 1 0 |a Hitoshi Ishizuka  |e author 
245 0 0 |a Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects 
260 |b BMC,   |c 2020-07-01T00:00:00Z. 
500 |a 10.1186/s40360-020-00423-4 
500 |a 2050-6511 
520 |a Abstract Background To investigate the effects of coadministration of esaxerenone with amlodipine on the pharmacokinetics (PK) of each drug, and of esaxerenone on the PK of digoxin. Methods In three open-label, single-sequence, crossover studies, healthy Japanese males received single oral doses of esaxerenone 2.5 mg (Days 1, 15), with amlodipine 10 mg/day (Days 8-18) (Study 1, N = 24); single doses of amlodipine 2.5 mg (Days 1, 21), with esaxerenone 5 mg/day (Days 8-25) (Study 2; N = 20); or digoxin 0.25 mg/day (Days 1-15) with esaxerenone 5 mg/day (Days 11-15) (Study 3; N = 20). PK parameters and safety were assessed. Results Study 1: esaxerenone peak plasma concentration (Cmax) and time to Cmax were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h. Geometric least-squares mean (GLSM) ratios for Cmax, area under the plasma concentration-time curve (AUC) from zero to last measurable concentration and from zero to infinity for esaxerenone + amlodipine versus esaxerenone were 0.958, 1.154, and 1.173, respectively. Study 2: corresponding GLSM ratios for amlodipine + esaxerenone versus amlodipine were 1.099, 1.185, and 1.214. Study 3: esaxerenone did not markedly alter digoxin PK. GLSM ratios for Cmax, trough plasma concentration, and AUC during a dosing interval for digoxin versus esaxerenone + digoxin were 1.130, 1.088, and 1.072, respectively. Conclusions No drug-drug interactions are expected during combination therapy with esaxerenone and either amlodipine or digoxin, based on a lack of any clinically relevant PK changes. Trial registration Studies 1 and 2: JapicCTI-163379 (registered on 20 September 2016); Study 3: JapicCTI-163443 (registered on 24 November 2016). 
546 |a EN 
690 |a Esaxerenone 
690 |a Drug interactions 
690 |a Pharmacokinetics 
690 |a Digoxin 
690 |a Amlodipine 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Toxicology. Poisons 
690 |a RA1190-1270 
655 7 |a article  |2 local 
786 0 |n BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020) 
787 0 |n http://link.springer.com/article/10.1186/s40360-020-00423-4 
787 0 |n https://doaj.org/toc/2050-6511 
856 4 1 |u https://doaj.org/article/c39e71805f0e44b8b24ece08b36c520b  |z Connect to this object online.